Laws & Regulations

How Will Trump's Policies Impact The Healthcare Industry's Future?
Regulatory & Compliance How Will Trump's Policies Impact The Healthcare Industry's Future?

With the advent of President Donald Trump's administration, various sectors of the healthcare industry have faced substantial policy changes that have caused uncertainty and apprehension about the future. A report from Fitch Ratings highlights numerous challenges that healthcare providers,

Trump Pushes for Enforced Healthcare Price Transparency in New Order
Regulatory & Compliance Trump Pushes for Enforced Healthcare Price Transparency in New Order

President Donald Trump has reinforced his commitment to healthcare price transparency with a new executive order. This directive mandates three key federal agencies to expedite the implementation and enforcement of the rules he introduced in 2019. The Departments of the Treasury, Labor, and Health

Judge Orders FDA and CDC to Restore Webpages on Gender Health Data
Regulatory & Compliance Judge Orders FDA and CDC to Restore Webpages on Gender Health Data

In a landmark decision that highlights the significance of accessible health information, District Judge John Bates ordered the Food and Drug Administration (FDA) and other federal health agencies to restore webpages previously removed under the Trump administration's executive orders. The affected

Is Medicare Advantage Reaching a Saturation Point in 2025?
Regulatory & Compliance Is Medicare Advantage Reaching a Saturation Point in 2025?

The Medicare Advantage (MA) market has been one of the most rapidly growing sectors in the healthcare industry over the past decade. As we navigate through 2025, there are clear signs indicating that this growth is beginning to decelerate. This analysis delves into the recent trends in MA

Potential NIH Funding Cuts Threaten U.S. Biotech Research and Innovation
Regulatory & Compliance Potential NIH Funding Cuts Threaten U.S. Biotech Research and Innovation

The future of U.S. biotechnology research faces uncertainty as potential funding cuts from the National Institutes of Health (NIH) are under consideration. The NIH has long been a critical cornerstone for foundational scientific research, facilitating early experimental work in academic

Is the FTC's Case Against Major PBMs Over Insulin Pricing Justified?
Regulatory & Compliance Is the FTC's Case Against Major PBMs Over Insulin Pricing Justified?

The ongoing legal battle between three leading pharmacy benefit managers (PBMs) — Express Scripts, Caremark, and Optum Rx — and the Federal Trade Commission (FTC) has garnered substantial attention. The core of the dispute revolves around allegations that these PBMs have engaged in anticompetitive

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later